Lytix Biopharma AS
World leader in oncolytic molecule therapy

Investordagene 2021, 20. October

Øystein Rekdal, CEO and Co-founder

Disclaimer

This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes.

The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated ('relevant persons'). Any person who is not a relevant person should not act or rely on the Presentation or any of its contents.

The Presentation does not constitute an offering of securities or otherwise constitute an invitation or inducement to any person to underwrite, subscribe for or otherwise acquire securities in the Company. The release, publication or distribution of the Presentation in certain jurisdictions may be restricted by law, and therefore persons in such jurisdictions into which this Presentation is released, published or distributed should inform themselves about, and observe, such restrictions.

The Presentation contains certain forward-looking statements relating to the business, products, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words "believes", expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in the Presentation, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. Neither the Company nor its employees provides any assurance that the assumptions underlying such forward-looking statements are free from errors nor does any of them accept any responsibility for the future accuracy of the opinions expressed in the Presentation or the actual occurrence of the forecasted developments. The Company assumes no obligation, except as required by law, to update any forward-looking statements or to conform these forward-looking statements to its actual results.

The Presentation contains information obtained from third parties. You are advised that such third party information has not been prepared specifically for inclusion in the Presentation and the Company has not undertaken any independent investigation to confirm the accuracy or completeness of such information.

An investment in the Company involves risk, and several factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by statements and information in the Presentation, including, among others, the risk factors described in the Company's information document dated 14 June 2021. Should any risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the Presentation.

No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither the Company nor its directors or employees accepts any liability whatsoever arising directly or indirectly from the use of the Presentation.

By attending or receiving the Presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business.

The Presentation speaks as of October 20, 2021. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date.

FIRST IN CLASS

Unique therapeutic approach

Universal mechanism of action

Solves the challenges caused by tumor heterogeneity

SAFETY AND EFFICACY DEMONSTRATED

Complete remission in animal models

Promising efficacy signals in patients

LTX-315 an ideal combination partner for checkpoint inhibitors

ENTERING PHASE II STUDIES IN U.S.

LTX-315 in Phase II development

Ongoing clinical study in US led by # 1 cancer hospital globally

Targeting large patient populations

SCIENTIFIC VALIDATION

Confirmed by leading US and European research institutions

Nobel Price winner member of advisory board

COMMERCIAL VALIDATION

Commercial deal within skin cancer

US health specialist fund as cornerstone investor

Listed at Euronext Growth 2021

Lytix Biopharma

FIRST IN CLASS

Unique therapeutic approach

Universal mechanism of action

Solves the challenges caused by tumor heterogeneity

SAFETY AND EFFICACY DEMONSTRATED

Complete remission in animal models

Promising efficacy signals in patients

LTX-315 an ideal combination partners for checkpoint inhibitors

ENTERING PHASE II STUDIES IN U.S.

LTX-315 in Phase II development

Ongoing clinical study in US led by # 1 cancer hospital globally

Targeting large patient populations

SCIENTIFIC VALIDATION

Confirmed by leading US and European research institutions

Nobel Price winner member of advisory board

COMMERCIAL VALIDATION

Commercial deal within skin cancer

US health specialist fund as cornerstone investor

Lytix Biopharma

Our unique oncolytic molecules

LTX-315 — **Lead product**



LTX-401 — **Pipeline product**



Oncolytic molecules solve one of the major challenges in current cancer therapy



Tumors consist of many different cancer cells with different mutations

Lytix Biopharma

A new in situ vaccination principle

A cancer cell before treatment



A cancer cell after treatment



TREATED TUMOR

Exposure of mutations (tumor antigens) from all cancer cells

LYMPH NODE

Generating T cells that recognize the different mutations (tumor antigens)

BLOOD VESSELS

T cells enter the blood stream searching for cancer cells

NON-TREATED TUMOR

T cells infiltrate and eradicate distant cancer

Lytix Biopharma

FIRST IN CLASS

Unique therapeutic approach

Universal mechanism of action

Solves the challenges caused by tumor heterogeneity

SAFETY AND EFFICACY DEMONSTRATED

Complete remission in animal models

Promising efficacy signals in patients

LTX-315 an ideal combination partners for checkpoint inhibitors

ENTERING PHASE II STUDIES IN U.S.

LTX-315 in Phase II development

Ongoing clinical study in US led by # 1 cancer hospital globally

Targeting large patient populations

SCIENTIFIC VALIDATION

Confirmed by leading US and European research institutions

Nobel Price winner member of advisory board

COMMERCIAL VALIDATION

Commercial deal within skin cancer

US health specialist fund as cornerstone investor

Lytix Biopharma

LTX-315 is effective in “hard to treat” cancer models

B16F10 MELANOMA



BRAF MUTATED MELANOMA



No effect of chemotherapy or immune checkpoint inhibitors in BRAF mutated melanoma

Liao, Cell Stress, 2019

Proof of Principle - Anti cancer effects in distant non-treated tumors confirmed in cancer patients

Two tumors treated on right side



Local treatment generated T cells reduce size of other distant non-treated tumors

39 % reduction

82 % reduction

Spicer, Clin. Cancer Res., 2021

Lytix Biopharma

Proof of Principle - Anti cancer effects in distant non-treated tumors confirmed in cancer patients





Spicer, Clin. Cancer Res., 2021

Lytix Biopharma

Immune checkpoint inhibitors solve a different problem in cancer therapy



Some cancers can protect themselves by activating brakes in the immune system

Immune checkpoint inhibitors cure some patients

MALIGNANT MELANOMA

60-89%



TRIPLE NEGATIVE BREAST CANCER

82-95%



HEAD & NECK

82-87%

SOFT TISSUE SARCOMA

82-92%

Responders

Failures

Lytix Biopharma

Immune checkpoint inhibitors solve a different problem in cancer therapy



Immune checkpoint inhibitors
can remove these brakes and keep the immune system ON

Immune checkpoint inhibitors cure some patients



Lytix Biopharma

Combination therapy solves both problems and helps more patients



Oncolytic molecules

generate T cells that recognize different cancer cells

+

Immune checkpoint inhibitors

keeps the brakes off and make the T cells work more efficiently

Lytix Biopharma

FIRST IN CLASS

Unique therapeutic approach

Universal mechanism of action

Solves the challenges caused by tumor heterogeneity

SAFETY AND EFFICACY DEMONSTRATED

Complete remission in animal models

Promising efficacy signals in patients

LTX-315 an ideal combination partners for checkpoint inhibitors

ENTERING PHASE II STUDIES IN U.S.

LTX-315 in Phase II development

Ongoing clinical study in US led by # 1 cancer hospital globally

Targeting large patient populations

SCIENTIFIC VALIDATION

Confirmed by leading US and European research institutions

Nobel Price winner member of advisory board

COMMERCIAL VALIDATION

Commercial deal within skin cancer

US health specialist fund as cornerstone investor

Lytix Biopharma

Clinical study with LTX-315 and the immune checkpoint inhibitor pembrolizumab is ongoing in US

- The study is led by MD Anderson Hospital
  - *Ranks as No. 1 globally in cancer care*

A pipeline of molecules with high commercial potential

Product candidate	Combination partner	Population	Preclinical	Phase I	Phase II	Phase III	Collaborations
LTX-315	**ATLAS-IT-05** Pembrolizumab (Keytruda®)	Patients progressed on checkpoint inhibitors	→	→	→		THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
	ATLAS-IT-04 Adoptive T-cell therapy	Advanced soft tissue sarcoma	→	→	→		REGION H Herlev Hospital
LTX-401	Monotherapy	Liver cancer	→				aptuit
A unique technology platform	**Inspired by nature** Based on the scientific concepts of naturally occurring host defense proteins already successful oncolytic virus			**Improved by science** Designed to mimic natural defense mechanisms and prime the immune system. Simple to manufacture, handle and administer.			

Lytix targets large market opportunities

HEAD AND NECK CANCER

130.000*
new patients diagnosed

3.7 Bn USD*
estimated indication value

LIVER CANCER

260.000*
new patients diagnosed

5.3 Bn USD*
estimated indication value



MALIGNANT MELANOMA

200.000*
new patients diagnosed

5.5 Bn USD*
estimated indication value

BREAST CANCER

970.000*
new patients diagnosed

12.2 Bn USD*
estimated indication value

** GLOBALDATA REPORTS. Estimated annual diagnosed patients in 2026 and onwards, and the value of the total forecasted drug sales in the indication*

Lytix Biopharma

FIRST IN CLASS

Unique therapeutic approach

Universal mechanism of action

Solves the challenges caused by tumor heterogeneity

SAFETY AND EFFICACY DEMONSTRATED

Complete remission in animal models

Promising efficacy signals in patients

LTX-315 an ideal combination partners for checkpoint inhibitors

ENTERING PHASE II STUDIES IN U.S.

LTX-315 in Phase II development

Ongoing clinical study in US led by # 1 cancer hospital globally

Targeting large patient populations

SCIENTIFIC VALIDATION

Confirmed by leading US and European research institutions

Nobel Price winner member of advisory board

COMMERCIAL VALIDATION

Commercial deal within skin cancer

US health specialist fund as cornerstone investor

Lytix Biopharma

Science behind Lytix' technology documented by world leading cancer research institutions

National Cancer Institute at the National Institutes of Health

Institut de cancérologie GUSTAVE ROUSSY VILLEJUIF - www.igr.fr

STANFORD SCHOOL OF MEDICINE

Lytix Biopharma

Oslo University Hospital Norwegian Radium Hospital

Weill Cornell Medicine

HARVARD UNIVERSITY

Multiple collaborations leading to 50+ peer reviewed scientific publications, demonstrating the potential of oncolytic molecules

Nobel laureate Jim Allison, who discovered the first immune checkpoint inhibitor, is a member of our scientific advisory board

"The ability of an activated immune response to generate a **diverse** T-cell repertoire that adapts to **heterogeneous** and genetically unstable tumors (…) make it **absolutely essential** to expand our efforts to find rational **combinations** to unleash antitumor immune responses for the benefit of cancer patients."

Jim Allison

- 2018 – Recipient of the Nobel price for the discovery of the first immune checkpoint inhibitor
- 2019 – Member of Lytix Advisory Board

Sharma, Science 2015

FIRST IN CLASS

Unique therapeutic approach

Universal mechanism of action

Solves the challenges caused by tumor heterogeneity

SAFETY AND EFFICACY DEMONSTRATED

Complete remission in animal models

Promising efficacy signals in patients

LTX-315 an ideal combination partners for checkpoint inhibitors

ENTERING PHASE II STUDIES IN U.S.

LTX-315 in Phase II development

Ongoing clinical study in US led by # 1 cancer hospital globally

Targeting large patient populations

SCIENTIFIC VALIDATION

Confirmed by leading US and European research institutions

Nobel Price winner member of advisory board

COMMERCIAL VALIDATION

Commercial deal within skin cancer

US health specialist fund as cornerstone investor

Lytix Biopharma

Lytix investor - the US healthcare specialist PBM Capital – invest in game changing technologies



Our technology already commercially validated

- US-based biotech focused on novel treatments for skin diseases
- License of LTX-315 for the treatment of certain skin cancers
- Regulatory milestones based on development goals and sales milestones at >100 mill. USD
- Royalty rates from the low double-digits to the mid-teens based on net sales USD

Why we will succeed

UNIQUE APPROACH

Lytix's molecules represent the missing piece

Ideal combination partners for checkpoint inhibitors

SCIENCE

Science confirmed by top notch US and European cancer research institutions

Nobel Laureate advisory board member

VALIDATION

Commercial deal within skin cancer

US health specialist fund as cornerstone investor

EXECUTION

Management Board
Advisory Board
Competent investors

Ongoing clinical study in US led by No 1 cancer hospital